Cardiotoxicity in patients with metastatic melanoma treated with BRAF/MEK inhibitors: a real-world analysis of incidence, risk factors, and reversibility

Cardiotoxicity in patients with metastatic melanoma treated with BRAF/MEK inhibitors: a real-world analysis of incidence, risk factors, and reversibility

Background: BRAF/MEK inhibitors (BRAFi/MEKi) improve outcome in patients with BRAF-mutated metastatic melanoma but are associated with cardiotoxicity, leading to a decline in left ventricular ejection fraction (LVEF). This study aimed to evaluate the incidence, timeline, risk factors, and reversibil...

Full description

Saved in:
Bibliographic Details
Main Authors: Jonas K. Oddershede, Ida K. Meklenborg, Lars Bastholt, Louise M. Guldbrandt, Henrik Schmidt, Rasmus B. Friis
Format: Article
Language:English
Published: Medical Journals Sweden 2025-04-01
Series:Acta Oncologica
Subjects:
BRAF/MEK inhibition
cardiotoxicity
malignant melanoma
echocardiography
multigated acquisition scan
oncocardiology
Online Access:https://medicaljournalssweden.se/actaoncologica/article/view/42567
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://medicaljournalssweden.se/actaoncologica/article/view/42567

Similar Items